[October 11, 2017]

Elixir Medical Corporation to Unveil Game-Changing DynamXTM Metallic Stent at the 29th Transcatheter Cardiovascular Therapeutics Conference

Elixir Medical Corporation, a leader in the development of breakthrough adaptive remodeling technologies designed to mimic the normal arterial function after cardiovascular and peripheral vascular disease intervention, announced today it will unveil a game-changing metallic drug eluting stent (DES) platform at this year's Transcatheter Cardiovascular Therapeutics (TCT) conference in Denver, which runs from October 29 - November 2.

This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171011005323/en/

DynamX is a 71 microns thin metallic DES designed to match the ease of use and acute performance of state-of-the-art DES. Unlike DES, however, DynamX allows the vessel to exhibit its normal pulsatile motion and adaptive remodeling capabilities. Elixir will be sharing for the first time the concept, design, data from preclinical testing, and clinical program for its DynamX ^TM Stent at a signature evening symposium on Monday, October 30^th 6:00 - 8:00 pm.

"DynamX ushers a new era of transformation from the current metallic stents which cage the vessel into stents that allow pulsatile motion and adaptive remodeling, mimicking the normal vessel function of patients," said Motasim Sirhan, founder, and CEO of Elixir Medical. "Elixir continues its commitment to developing breakthrough adaptive remodeling technologies to better address patient needs around the world beyond the capabilities of today's technologies."

Elixir continues to advance its fully bioresorbable scaffold programs and will present its latest trial results throughout TCT.

Below are the details for Elixir programs and activities at TCT 2017 in Mountain Daylight Time (MDT):

Monday, October 30:

11 a.m. - Mile High Ballroom 2A-3A, Ballroom Level
Drug Eluting Scaffold with an Absorbable Platform for Primary Lower Extremity Arterial Revascularization: DESappear Study Initial Results with Prava
Thomas Zeller, MD, Universitäts-Herzzentrum Freiburg, Bad Krozingen, Germany
6 p.m. - 8:00 p.m., Hyatt Regency Centennial Ballroom D-E
ELIXIR SYMPOSIUM: DynamX ^TM Redefinin Interventional Cardiology

Co-Chairs and Faculty

• Martin B. Leon MD, New York-Presbyterian Hospital/Columbia University Medical Center, New York, NY, USA
• Dean J. Kereiakes, MD, The Christ Hospital, Cincinnati, OH, USA
• Stefan Verheye, MD, PH.D., Antwerp Cardiovascular Centre, ZNA, Antwerp, Belgium
• Roxana Mehran, MD, Icahn School of Medicine at Mount Sinai, New York, NY, USA

Agenda

• PCI (News - Alert) vision and Introducing the DynamX stent
• DynamX Pre-Clinical Testing
• Limitations of Current DES: DynamX in perspective
• DynamX Clinical Program Overview
• Q & A
• Take Home Message

Attendees are encouraged to register early to attend the Elixir unveiling on Monday evening.

Tuesday, October 31:

9:54 a.m. - Moderated Posters 4, Exhibit Hall, Exhibit Level
Multi-Center Evaluation of a Novel 120 µm Novolimus-Eluting, Fully Bioresorbable Coronary Scaffold: First Report of 6-month Imaging and 12-Month Clinical Results
Stefan Verheye, MD, PHD, Antwerp Cardiovascular Centre, ZNA, Antwerp, Belgium

10:06 a.m. - Moderated Posters 4, Exhibit Hall, Exhibit Level
Multi-Center, Post-marketing Evaluation of the Elixir DESolve Novolimus Eluting Bioresorbable Coronary Stent System: 24-month Results from the DESolve PMCF Study
Holger Nef, MD, Ph.D., University Hospital Giessen, Giessen, Germany

12:06 p.m. - Moderated Posters 3, Exhibit Hall, Exhibit Level
Drug Eluting Scaffold with an Absorbable Platform for Primary Lower Extremity Arterial Revascularization - DESappear Study Initial Results
Marc Bosiers, MD, St. Blasius Hospital, Dendermonde, Belgium

1:45 p.m. - Room 709/711, Meeting Room Level
Prospective, Multicenter Evaluation of the DESolve^® Novolimus-Eluting Bioresorbable Coronary Scaffold - Imaging Outcomes and Five-Year Clinical and Imaging Results
Stefan Verheye, MD, PH.D., Antwerp Cardiovascular Centre, ZNA, Antwerp, Belgium

3:21 p.m. - Room 210, Meeting Room Level, Virtual Didactic
The DESyne Novolimus-Eluting Coronary Stent: Results From the Excella Trials
Javaid Iqbal, MD, South Yorkshire Cardiothoracic Centre, Sheffield Teaching Hospitals NHS Foundation Trust Sheffield, United Kingdom

4:33 p.m. - Mile High Ballroom 4E-4F, Ballroom Level
DESolve Nx, Cx, and Amity: A Family of Progressively Thinner-Strut PLLA-Based BRS With Novel Properties
Stefan Verheye, MD, PH.D., Antwerp Cardiovascular Centre, ZNA, Antwerp, Belgium

7:05 p.m. - Hyatt Regency Denver at Colorado Convention Center Continental Ballroom F-H
A "Novel" Metallic DES with Bioresorbable Polymer- The Elixir DynamX Program
Martin B. Leon MD, New York-Presbyterian Hospital/Columbia University Medical Center, New York, NY, USA

7:40 p.m. - Hyatt Regency Denver at Colorado Convention Center Continental Ballroom F-H
The BRS Landscape: Where do we Stand? (ABSORB, MAGNITUDE, DESolve, FANTOM, and DREAMS-2G)
Gregg W. Stone, MD, New York-Presbyterian Hospital/Columbia University Medical Center, New York, NY, USA

About Elixir Medical Corporation

Elixir Medical Corporation, a privately funded company based in Milpitas, California, has developed the broadest portfolio of coronary stents and scaffolds including DESyne, DESyne BD, DESolve, DESolve CX, DESolve NXT, Prava, and the breakthrough DynamX product platform. The company's next-generation drug-eluting stent systems and bioresorbable coronary scaffolds are designed to mimic the normal pulsatile motion and adaptive remodeling capabilities of the vessel after intervention to better address patient needs. For more information, visit www.elixirmedical.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20171011005323/en/

[ Back To TMCnet.com's Homepage ]